Xcout Intel
AdipoPharma
AdipoPharma is a French biotech company dedicated to understanding the role of adipocyte cells in diabetes, focusing on lipid biosynthesis and whole-body metabolic health.
Subscribe to see AdipoPharma’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
AdipoPharma at a glance
AdipoPharma is a biotechnology company headquartered in France. Its most recent funding round, Series A, closed in January 2023. Xcout tracks 11 named people at AdipoPharma, including Michael J. Fare (Chief Operating Officer).
AdipoPharma leadership
- Michael J. FareChief Operating Officer
- Catherine PerotChief Financial Officer
- Tarekegn G. HiwotChief Medical Officer
- Vincent MarionFounder, President & CEO
- Virginie BarthelDirector of Clinical Operations
- Martine BrandtOffice Manager
5 more named people on record for AdipoPharma, with roles, board committees and tenure — see the full roster →
AdipoPharma funding rounds
Every round on record:
| Date | Round | Amount | Investors |
|---|---|---|---|
| Series A | Undisclosed | 3 named |
Who invested in each round, lead investors, valuations and the co-investor graph — open the full funding history →
Investors
AdipoPharma competitors
A few of AdipoPharma's closest competitors — see the full list of competitors and alternatives →
Adipo Therapeutics is a biotechnology company developing treatments for obesity and metabolic-related diseases. The company utilizes Notch-inhibiting nanoparticles to convert energy-storing white fat into energy-burning brown fat to increase energy expenditure and resting metabolic rate.
Adocia is a clinical-stage biotechnology company that develops innovative formulations of proteins, peptides, and metabolic hormones. The company specializes in creating treatments for diabetes and obesity, as well as immunoprotective scaffolds for cell therapies.
DiogenX is a preclinical-stage biotechnology company headquartered in Marseille, France, with research laboratories in Nice, dedicated to developing novel treatments for diabetes.
Syntis Bio, Inc. is a clinical-stage biopharmaceutical company headquartered in Boston, Massachusetts, dedicated to revolutionizing oral therapies for obesity and metabolic diseases.
Carmot Therapeutics, Inc. is a biopharmaceutical company headquartered in Berkeley, California, focused on discovering and developing innovative treatments for metabolic diseases and obesity.
Biophytis is a clinical-stage biotechnology company that develops transformational therapies to improve longevity and treat age-related diseases. The company utilizes an AI-driven research platform to discover novel drug candidates, with advanced clinical programs focusing on sarcopenia and obesity.
Get AdipoPharma's news by email
Funding rounds, acquisitions, new executives, launches and expansions, each with a two-line summary and a link to the source. One short email a day, only when there is news.
Free: up to 5 companies, daily. Subscribers also follow whole sectors and saved filters (M&A in Israel, AI funding…), get instant alerts, in-app notifications and signed webhooks, and open the full profile behind every name. Subscribe →
Share this card
Post the link and the card appears automatically — each network fetches the image itself.
More on AdipoPharma in Xcout Intel
- 11 named people with titles, LinkedIn and board committees
- 1 funding round with the investors in each, and who they co-invest with
- The full competitor set, tracking, exports and API access